138 related articles for article (PubMed ID: 19200053)
1. The changing face of HDAC inhibitor depsipeptide.
Zhou W; Zhu WG
Curr Cancer Drug Targets; 2009 Feb; 9(1):91-100. PubMed ID: 19200053
[TBL] [Abstract][Full Text] [Related]
2. From discovery to the coming generation of histone deacetylase inhibitors.
Yoshida M; Matsuyama A; Komatsu Y; Nishino N
Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
[TBL] [Abstract][Full Text] [Related]
3. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Chang J; Varghese DS; Gillam MC; Peyton M; Modi B; Schiltz RL; Girard L; Martinez ED
Br J Cancer; 2012 Jan; 106(1):116-25. PubMed ID: 22158273
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
5. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
6. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.
Kwon HJ; Kim MS; Kim MJ; Nakajima H; Kim KW
Int J Cancer; 2002 Jan; 97(3):290-6. PubMed ID: 11774279
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Sutheesophon K; Nishimura N; Kobayashi Y; Furukawa Y; Kawano M; Itoh K; Kano Y; Ishii H; Furukawa Y
J Cell Physiol; 2005 May; 203(2):387-97. PubMed ID: 15515013
[TBL] [Abstract][Full Text] [Related]
10. From natural products to small molecule ketone histone deacetylase inhibitors: development of new class specific agents.
Jones P; Steinkühler C
Curr Pharm Des; 2008; 14(6):545-61. PubMed ID: 18336299
[TBL] [Abstract][Full Text] [Related]
11. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Zhu WG; Lakshmanan RR; Beal MD; Otterson GA
Cancer Res; 2001 Feb; 61(4):1327-33. PubMed ID: 11245429
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors from microorganisms: the Astellas experience.
Masuoka Y; Shindoh N; Inamura N
Prog Drug Res; 2008; 66():335, 337-59. PubMed ID: 18416310
[TBL] [Abstract][Full Text] [Related]
14. FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Konstantinopoulos PA; Vandoros GP; Papavassiliou AG
Cancer Chemother Pharmacol; 2006 Nov; 58(5):711-5. PubMed ID: 16435156
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone deacetylases in neuroblastoma.
Witt O; Deubzer HE; Lodrini M; Milde T; Oehme I
Curr Pharm Des; 2009; 15(4):436-47. PubMed ID: 19199971
[TBL] [Abstract][Full Text] [Related]
16. The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
Wang H; Zhou W; Zheng Z; Zhang P; Tu B; He Q; Zhu WG
DNA Repair (Amst); 2012 Feb; 11(2):146-56. PubMed ID: 22112863
[TBL] [Abstract][Full Text] [Related]
17. Trithiocarbonates as a novel class of HDAC inhibitors: SAR studies, isoenzyme selectivity, and pharmacological profiles.
Dehmel F; Weinbrenner S; Julius H; Ciossek T; Maier T; Stengel T; Fettis K; Burkhardt C; Wieland H; Beckers T
J Med Chem; 2008 Jul; 51(13):3985-4001. PubMed ID: 18558669
[TBL] [Abstract][Full Text] [Related]
18. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of non-hydroxamate histone deacetylase inhibitors: identification of a selective histone acetylating agent.
Suzuki T; Matsuura A; Kouketsu A; Hisakawa S; Nakagawa H; Miyata N
Bioorg Med Chem; 2005 Jul; 13(13):4332-42. PubMed ID: 15927839
[TBL] [Abstract][Full Text] [Related]
20. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
